Medcura

Focus: Medcura is an early-stage biotech founded in 2024 focused on bleeding control and hemostasis solutions. The company is pre-revenue and currently in Series A funding stage.

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Medcura

AI assessmentNot Hiring

No open roles listed right now. Follow Medcura to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

hm-P bandage

Hemostasis

N/A

Clinical Trials (1)

NCT04593667Randomized Study of Accelerated Radial Arterial Hemostasis

N/A

Help build intelligence for Medcura

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity to build bleeding control franchise from inception in a newly founded (2024) company with clear focus
Access to early-stage innovation in hemostasis with active clinical trial program (1 trial active)
Potential for significant equity upside during Series A stage before later funding rounds dilute ownership

Watch Out For

Extreme early-stage risk: founded in 2024 with no revenue, no employees data, and minimal funding transparency
Minimal pipeline visibility: only 1 program (hm-P bandage) in early development with no phase designation, creating execution uncertainty
No active hiring and unproven management team in nascent organization with no disclosed funding amount

Generated by Claude from Medcura's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 1 clinical trial

Publications: 4 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(4)

Recent peer-reviewed publications with author affiliations at this company

An investigational time-course study using an in vivo ovine laminectomy model for the neurohistopathological evaluation of hemostatic agents.

Annals of translational medicine

2025

PMID:40689067

The Evaluation of Gingival Crevicular Fluid Biomarkers as Predictors of Gingival Enlargement in Patients Undergoing Fixed Orthodontic Treatment: A Prospective Study.

Cureus

2024

PMID:39717295